Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Repeated Intravenous Infusions in Patients With Malignant Solid Tumors Expressing B7-H6

Summary

The purpose of this Phase I study is to evaluate the safety and tolerability of BI 765049 alone and in combination with BI 754091 in patients with advanced solid tumors, including pancreatic cancer.

General Information

NCT#: NCT04752215
Study ID: 1454-0001
Trial Phase: Phase I

Trial Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Therapies Used in This Trial: BI 765049, BI 754091

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search